Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company that regularly reports updates on its pipeline of seven programs targeting novel mechanisms of action for brain diseases and other underserved, prevalent diseases. News about Neumora often centers on clinical trial progress, preclinical data, financial results and corporate presentations, giving investors and observers insight into how its development strategy is unfolding.
Recent press releases highlight multiple areas of activity. The company has reported positive Phase 1b results for NMRA-511, an oral, highly potent, brain-penetrant and selective vasopressin 1a receptor antagonist being evaluated for agitation associated with Alzheimer’s disease. It has also provided frequent updates on navacaprant, a kappa opioid receptor antagonist in Phase 3 KOASTAL studies for major depressive disorder, including plans for consolidated topline readouts.
Neumora’s news flow also covers its M4 muscarinic receptor positive allosteric modulator franchise, with Phase 1 SAD/MAD studies of NMRA-861 and NMRA-898 designed to assess safety, tolerability and pharmacokinetics in healthy adults and people with stable schizophrenia. In addition, the company has announced preclinical diet-induced obesity data for NMRA-215, a highly brain-penetrant oral NLRP3 inhibitor prioritized for obesity, and has outlined plans to move this program into clinical testing.
Beyond scientific and clinical milestones, Neumora issues regular quarterly financial results, business updates and notices of participation in healthcare and investor conferences. The NMRA news page on Stock Titan aggregates these announcements so readers can follow developments in Alzheimer’s disease agitation, major depressive disorder, schizophrenia, obesity and other areas where Neumora is active.
Neumora Therapeutics (Nasdaq: NMRA) announced a roundtable discussion on the neuropsychiatric treatment landscape and the role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The event, featuring leading experts, will take place on September 12, 2024, at 8:00 a.m. ET.
The discussion will focus on the potential of navacaprant, Neumora's KORA candidate, in treating neuropsychiatric disorders. The company is currently conducting a Phase 3 KOASTAL program for navacaprant in major depressive disorder (MDD) and a Phase 2 study in bipolar depression. Neumora expects to report topline data from the KOASTAL-1 Phase 3 study in Q4 2024.
The event will cover topics including Neumora's mission and pipeline, the role of kappa opioid receptors in MDD, navacaprant's Phase 2 data, and potential indications beyond MDD and bipolar depression.
Neumora Therapeutics (NMRA) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Phase 3 KOASTAL-1 study data for navacaprant in major depressive disorder (MDD) expected in Q4 2024.
2. Ongoing clinical studies in MDD, bipolar depression, and Alzheimer's disease agitation.
3. Strong financial position with $371.6 million in cash, cash equivalents, and marketable securities, expected to support operations into 2026.
4. Q2 2024 R&D expenses increased to $48.6 million from $32.8 million in Q2 2023.
5. Net loss for Q2 2024 was $58.7 million, compared to $38.5 million in Q2 2023.
6. Narrowed guidance to submit an IND for an additional M4 compound in H1 2025.
Neumora Therapeutics has initiated a Phase 1b study evaluating NMRA-511 for treating agitation in Alzheimer's disease (AD). NMRA-511, an oral antagonist of the vasopressin 1a receptor (V1aR), was well-tolerated in prior studies with no serious adverse events. The Phase 1b study, starting with healthy elderly adults and then AD patients, aims to assess safety, tolerability, and efficacy. The study will measure changes in agitation using the Cohen-Mansfield Agitation Inventory. Neumora expects to report topline data in the second half of 2025.
Neumora Therapeutics has initiated a Phase 2 clinical trial for navacaprant, targeting bipolar depression. The company aims to evaluate the safety and efficacy of the 80 mg oral KOR antagonist, which previously showed promise in treating major depressive disorder (MDD). The trial will involve 60 patients and focus on improvements in depressive symptoms and anhedonia, with results expected in the second half of 2025. Additionally, navacaprant is in Phase 3 development for MDD, with data from the KOASTAL-1 study anticipated in Q4 2024. This study could lead to broader applications for navacaprant in bipolar disorder.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) reported strong financial results for Q1 2024 with $423.0 million in cash, guidance narrowed to Q4 2024 for Phase 3 data from KOASTAL-1 study with navacaprant in MDD, and multiple upcoming clinical study initiations. The company is well-positioned with a robust pipeline targeting neuropsychiatric and neurodegenerative diseases.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024 and RBC Capital Markets Global Healthcare Conference. The company's therapeutic pipeline includes seven clinical and pre-clinical brain disease programs.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
